PUBLISHER: IMARC | PRODUCT CODE: 1702010
PUBLISHER: IMARC | PRODUCT CODE: 1702010
The global joint reconstruction devices market size reached USD 28.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 42.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.51% during 2025-2033.
Joint reconstruction devices are primarily designed for restoring the movement of joints, providing them with structural support either temporarily or permanently, or aiding in tissue reconstruction. These devices are utilized separately or together with one or more implantable medical devices as a replacement in whole or part for shoulder, hip, or knee joints. Nowadays, joint disorders like osteoarthritis (OA) are widely becoming prevalent on account of sedentary lifestyles and unhealthy dietary patterns of individuals. This is positively influencing the requirement for joint reconstruction devices across the globe.
The rising geriatric population around the world represents one of the key factors stimulating the growth of the market. Moreover, the advent of advanced, emerging technologies, such as 3D printing, robotics, and augmented reality (AR), are making joint reconstruction safer, more accurate, and efficient. 3D printing is increasingly being used in creating customized bio models (replicas of patient anatomy), devices, and implants to plan and simulate complex surgical procedures. This technology facilitates joint replacements associated with infection or the failure of a previous replacement joint. Besides this, robotic-assisted surgery is emerging as an innovative method for hip and knee arthroplasty as it offers enhanced component positioning, real-time information about soft tissue tensioning and balance, and restoration of hip length and offset. This, coupled with the increasing accidental or sports-related injuries that cause broken bones and dislocations, is strengthening the growth of the market. Apart from this, there is a rise in the number of individuals requiring total ankle replacement (TAR) and tibiotalar arthrodesis (TTA) for the surgical management of ankle arthritis, which is projected to drive the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aesculap Inc. (B. Braun Melsungen AG), Conformis Inc., Conmed Corporation, DJO Global Inc. (Enovis Corporation), Exactech Inc., Johnson & Johnson Services Inc, Kyocera Medical Technologies Inc. (Kyocera Corporation), Medacta International SA, Smith & Nephew plc, Stryker Corporation and Zimmer Biomet.